Lonza

The small molecule APIs entering the development pipeline are becoming ever more complex, and synthetic routes are getting longer as a result, making it more difficult for chemists to create efficient manufacturing processes. Computer-aided synthesis planning technologies have become important tools in designing better syntheses.   This is something Lonza is now addressing via its Route Scouting service that combines AI tools with our experts’ skills and our supply chain insight. One of these experts, Simon Wagschal, is teaming up with Elsevier Information Systems’ Juergen Swienty-Busch to give a webinar about how computer-aided synthesis planning tools can make a real difference in creating effective synthetic routes for these complex molecules.   The webinar is being hosted by Outsourced Pharma, and is free to attend. It’s taking place at 11am EDT/5pm CEST on Tuesday 30 July. You can register at https://lnkd.in/eXvez_GP

We are always looking for ways to make APIs more effectively, efficiently and safely. This is the focus of a new protocol developed by Simon Wagschal and the Advanced Chemistry Technologies team in Visp, in collaboration with scientists at the University of Graz in Austria. Fluorine atoms are often found in API molecules because they are very useful features to introduce and modify biological activity. However, fluorinating agents are hazardous to use, and the more selective modern ones are expensive. Simon and team, which also included Dominique M. Roberge and Clara Bovino at Lonza Visp, found they could use the cheap reagent sulfur tetrafluoride, and by running the reactions in a continuous flow reactor, the whole process was made much less hazardous. After this initial success, they have extended the methodology, and can now use it to make gem-difluoro compounds, where two fluorine atoms are attached to the same carbon atom. Numerous drugs contain gem-difluoro groups, but they are really challenging to make. But they managed to apply their fluorination methodology to the task, replacing the oxygen in a ketone with two fluorines. If you would like to know more about these exciting developments, the original methodology was published in the journal Organic Process Research & Development last December, https://lnkd.in/erkr-WHH. A paper describing the difluorination reaction has just been published by the same journal – and it’s been selected as editor’s choice. https://lnkd.in/e4AAn3nU If you’re interested in discovering more about how you can use this chemistry, get in touch with us to find out more. https://lnkd.in/euW435ff

Simon Wagschal talks about the evolving landscape of API and drug substance development and a trend towards longer synthetic routes. Read our recent R&D blog about a route scouting solution for these increasingly complex molecules, which combines AI-driven retrosynthetic analysis with the technical knowledge and experience of our experts. https://lnkd.in/erKxD8b7 #AHealthierWorld #Innovation #PharmaceuticalManufacturing #AI #SmallMolecules

Lonza is excited to attend Bioplus-Interphex Korea 2024 next week as a gold sponsor. Our colleagues from Biologics, Small Molecules and Cell & Gene will be available to discuss ways they can support your complex needs in drug development and manufacturing. On Wednesday 10th, Dr Yvette Stallwood will give an insightful presentation on how to navigate the road to first-in-human clinical trials: 📅 Wednesday, 10 July 🕝 1.20pm ⭐Optimising the Path to First-in-Human Clinical Trials: An Integrated Approach to Design and De-risk Your Candidate, Including ADCs Speaker: Yvette Stallwood, Head of Early Development Services You can meet us at Booth #M31 - we are excited to see you there #Lonza #LonzaBIO #LonzaSM #LonzaCGT #AHealthierWorld

Today, Wolfgang Wienand joins Lonza as our CEO. A proven leader, he brings a wealth of expertise and experience from almost two decades in senior leadership positions in the CDMO industry. We are looking forward to working with Wolfgang to meet and exceed the needs of our customers and their patients as we pursue our purpose to enable a healthier world.

Earlier this month, we experienced an incredible few days connecting with you at BIO International. We participated in engaging and insightful discussions, and thank everyone who connected with our team onsite in San Diego. We enjoyed meeting you at our booth, networking with you at our evening reception, and learning more about your biologics, cell and gene therapy and small molecule needs.   We look forward to further collaborating to drive positive change in our industry. See you in Boston in 2025! #BIO2024 #biologics #celltherapy #genetherapy #smallmolecules

At Lonza, Pride Month is our opportunity to recognize and celebrate the immense value that our diverse colleagues bring to our business. But for us, Pride is more than a month. We are working all the time to create a culture of inclusion and affirmation in which every colleague is safe and supported to be themselves and bring their best. This is how we make a meaningful difference together. #Lonza #PrideMonth #AMeaningfulDifference

Join our Lonza experts James Berrie and Eddy BERTHIER for an upcoming webinar, where they will explore innovative strategies and good practices to accelerate the pathway into clinical development for novel biotherapeutics. This session will delve into comprehensive and integrated drug substance/drug product DNA-to-IND programs designed to expedite development across various modalities, including monoclonal antibodies, bispecific antibodies, Fabs, Fc-fusions and non-Fc recombinant proteins. Register today: https://lnkd.in/e2F8X259 📅 Monday, 8 July 🕝 11am EDT / 5pm CET #Lonza #Biologics

Join us for a must-see webinar on the critical aspects of technology transfer of either biological drug substance or drug product. This session will delve into the strategies and best practices for seamless tech transfer processes, ensuring regulatory compliance, and maintaining product quality and consistency. We will explore real-world case studies highlighting innovative solutions to accelerate clinical tech transfer for drug products, enabling a released clinical batch within five months from kick-off. 📅 Thursday, 11 July, 2024 🕚 11am EDT / 5pm CET Register today: https://lnkd.in/engVg32Y Featured experts: Maolong Liu, Angela Armanni, Andrea Lei Leston #techTransfers #LonzaDPS #sterileDrugProduct #parenteralDrugProduct #drugProduct

We are pleased to share the June edition of Biologics In Focus, the biologics newsletter from Lonza. Each month we deliver deep analysis of industry trends, expert insights, and an overview of upcoming events - as well as the latest Lonza news and real world customer stories. This month's highlights include: -A webinar from early June on navigating a holistic approach to Container Closure Integrity for biologic drug products -An article from BioPharm International where Lonza experts talk about technological advances that are impacting current aseptic processes and improving time-to-market -A real customer case study from Levicept, discussing their experience with Lonza and how they built a strong relationship to deliver successful partnership outcomes Please do subscribe to ensure you receive the future editions of Biologics In Focus #LonzaBio #pharma #biotechnology #thePeoplePoweringBiologics